Looking for Nuvaxovid COVID vaccine in Ontario, Canada?
Ontario has been shipping #Nuvaxovid from Sanofi Canada this week (Oct. 26) to some pharmacies across the province. Email OPDPInfoBox@ontario.ca to ask for a list of pharmacies in your area that it was shipped to.🧵
Ontario has been shipping #Nuvaxovid from Sanofi Canada this week (Oct. 26) to some pharmacies across the province. Email OPDPInfoBox@ontario.ca to ask for a list of pharmacies in your area that it was shipped to.🧵
October 30, 2026 at 12:02 PM
Looking for Nuvaxovid COVID vaccine in Ontario, Canada?
Ontario has been shipping #Nuvaxovid from Sanofi Canada this week (Oct. 26) to some pharmacies across the province. Email OPDPInfoBox@ontario.ca to ask for a list of pharmacies in your area that it was shipped to.🧵
Ontario has been shipping #Nuvaxovid from Sanofi Canada this week (Oct. 26) to some pharmacies across the province. Email OPDPInfoBox@ontario.ca to ask for a list of pharmacies in your area that it was shipped to.🧵
Sanofi (SNY) Raises 2026 Growth Targets and Signals Bigger Deals
Sanofi (SNY) announced higher growth targets for 2026 under its new CEO, focusing on expanding through larger acquisitions…
https://newsstocks.live/news/sanofi-sny-raises-2026-growth-targets-and-signals-bigger-deals #Finance #Markets
Sanofi (SNY) announced higher growth targets for 2026 under its new CEO, focusing on expanding through larger acquisitions…
https://newsstocks.live/news/sanofi-sny-raises-2026-growth-targets-and-signals-bigger-deals #Finance #Markets
October 30, 2026 at 12:02 PM
Sanofi (SNY) Raises 2026 Growth Targets and Signals Bigger Deals
Sanofi (SNY) announced higher growth targets for 2026 under its new CEO, focusing on expanding through larger acquisitions…
https://newsstocks.live/news/sanofi-sny-raises-2026-growth-targets-and-signals-bigger-deals #Finance #Markets
Sanofi (SNY) announced higher growth targets for 2026 under its new CEO, focusing on expanding through larger acquisitions…
https://newsstocks.live/news/sanofi-sny-raises-2026-growth-targets-and-signals-bigger-deals #Finance #Markets
Sanofi lifts expectations for 2026 sales growth, looks to M&A reut.rs/4iftGaN
Sanofi lifts expectations for 2026 sales growth, looks to M&A
French drugmaker Sanofi said on Friday it expects sales to grow by a "low-teens percentage" this year, up from a previous forecast of 10% sales growth, banking on strong demand for its blockbuster asthma drug Dupixent.
reut.rs
October 30, 2026 at 7:05 AM
Sanofi lifts expectations for 2026 sales growth, looks to M&A reut.rs/4iftGaN
Woah, check out this extensive list of pharmacies across Canada @stillcovidingca.bsky.social has compiled to help you find the Sanofi Nuvaxovid Covid vaccine!
Thanks for looking out for us, Still COVIDing Canada!! 🫶😷
stillcoviding.ca/en/resources...
Thanks for looking out for us, Still COVIDing Canada!! 🫶😷
stillcoviding.ca/en/resources...
List of pharmacies
stillcoviding.ca
November 1, 2026 at 1:40 AM
Woah, check out this extensive list of pharmacies across Canada @stillcovidingca.bsky.social has compiled to help you find the Sanofi Nuvaxovid Covid vaccine!
Thanks for looking out for us, Still COVIDing Canada!! 🫶😷
stillcoviding.ca/en/resources...
Thanks for looking out for us, Still COVIDing Canada!! 🫶😷
stillcoviding.ca/en/resources...
Sanofi agrees to settle antitrust case in US over diabetes drug Lantus reut.rs/4zQuQzi
Sanofi agrees to settle antitrust case in US over diabetes drug Lantus
Sanofi has reached a tentative settlement to resolve long-running claims by drug wholesalers that the pharmaceutical company used an improper patent listing to suppress competition to its diabetes treatment Lantus.
reut.rs
October 28, 2026 at 9:00 PM
Sanofi agrees to settle antitrust case in US over diabetes drug Lantus reut.rs/4zQuQzi
sans aucune contrepartie (c'est pas Sanofi qui avait licencié la moitié de sa R&D française juste après avoir palpé plusieurs millions de CIR?)
October 30, 2026 at 9:34 AM
sans aucune contrepartie (c'est pas Sanofi qui avait licencié la moitié de sa R&D française juste après avoir palpé plusieurs millions de CIR?)
Ezt a lakast nezte meg nemreg egy kolleganom, azt mondta a kornyekkel baj nincs, de a Sanofi gyar kozel van, es mondjuk o kenyes arra, hogy mik kerulnek igy ki a levegobe
October 31, 2026 at 2:58 PM
Ezt a lakast nezte meg nemreg egy kolleganom, azt mondta a kornyekkel baj nincs, de a Sanofi gyar kozel van, es mondjuk o kenyes arra, hogy mik kerulnek igy ki a levegobe
#$REGN · Regeneron reports $1.9 billion profit and expands Sanofi deal
Regeneron Pharmaceuticals reported third-quarter 2026 revenue of $5.1 billion, up 36.3% from a year earlier. Net income rose 33.5% to $1.9 billion. Regeneron also expanded its collaboration agreement with…
#stocks #investing
Regeneron Pharmaceuticals reported third-quarter 2026 revenue of $5.1 billion, up 36.3% from a year earlier. Net income rose 33.5% to $1.9 billion. Regeneron also expanded its collaboration agreement with…
#stocks #investing
Regeneron reports $1.9 billion profit and expands Sanofi deal
Regeneron Pharmaceuticals reported third-quarter 2026 revenue of $5.1 billion, up 36.3% from a year earlier. Net income rose 33.5% to $1.9 billion. Regeneron also expanded its collaboration agreement with Sanofi, receiving $1.0 billion in up-front payments.
insiderpost.org
October 31, 2026 at 8:41 AM
#$REGN · Regeneron reports $1.9 billion profit and expands Sanofi deal
Regeneron Pharmaceuticals reported third-quarter 2026 revenue of $5.1 billion, up 36.3% from a year earlier. Net income rose 33.5% to $1.9 billion. Regeneron also expanded its collaboration agreement with…
#stocks #investing
Regeneron Pharmaceuticals reported third-quarter 2026 revenue of $5.1 billion, up 36.3% from a year earlier. Net income rose 33.5% to $1.9 billion. Regeneron also expanded its collaboration agreement with…
#stocks #investing
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 ...
->Morningstar | More on "Novavax Sanofi vaccine partnership milestone" at BigEarthData.ai
->Morningstar | More on "Novavax Sanofi vaccine partnership milestone" at BigEarthData.ai
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 ...
The combination vaccine candidate evaluated in this trial pairs Sanofi's leading high-dose flu vaccine with Novavax's differentiated COVID-19 vaccine Significant potential value remains in Sanofi partnership via additional future opportunities for milestones and royalties GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's COVID-19 vaccine, Nuvaxovid™. Sanofi's Phase 3 trial, being conducted in Europe, is assessing the safety and immunogenicity of Nuvaxovid in combination with Sanofi's marketed Efluelda/Fluzone® High-Dose vaccine in adults aged 60 and older. "Novavax and Sanofi continue to successfully execute on the opportunities afforded by our partnership. To date, the partnership has generated over $1 billion in revenue for Novavax,"2 said John C. Jacobs, President and Chief Executive Officer, Novavax. "Sanofi has stated that they intend to be one of the first movers in the combination vaccine segment, and Novavax believes this is an important step toward that goal. We are excited about the value we are building together with our partners." Under the collaboration and license agreement, for Nuvaxovid, Novavax is eligible to receive royalties on Sanofi sales and a $75 million...
www.morningstar.com
October 30, 2026 at 7:37 AM
💉 #pharma
🇫🇷 Sanofi relève encore ses perspectives 2026 : croissance des ventes « low-teens », BNPA des activités « mid-teens ».
T3 à changes constants : CA 14,4 Md€, +14,3 % ; #Dupixent 5,7 Md€, +34,8 %, 39 % des ventes ; #Beyfortus −15,4 % (US −39,3 %).
midgardfinance.com/companies/SAN.PA/
🇫🇷 Sanofi relève encore ses perspectives 2026 : croissance des ventes « low-teens », BNPA des activités « mid-teens ».
T3 à changes constants : CA 14,4 Md€, +14,3 % ; #Dupixent 5,7 Md€, +34,8 %, 39 % des ventes ; #Beyfortus −15,4 % (US −39,3 %).
midgardfinance.com/companies/SAN.PA/
October 30, 2026 at 11:20 AM
💉 #pharma
🇫🇷 Sanofi relève encore ses perspectives 2026 : croissance des ventes « low-teens », BNPA des activités « mid-teens ».
T3 à changes constants : CA 14,4 Md€, +14,3 % ; #Dupixent 5,7 Md€, +34,8 %, 39 % des ventes ; #Beyfortus −15,4 % (US −39,3 %).
midgardfinance.com/companies/SAN.PA/
🇫🇷 Sanofi relève encore ses perspectives 2026 : croissance des ventes « low-teens », BNPA des activités « mid-teens ».
T3 à changes constants : CA 14,4 Md€, +14,3 % ; #Dupixent 5,7 Md€, +34,8 %, 39 % des ventes ; #Beyfortus −15,4 % (US −39,3 %).
midgardfinance.com/companies/SAN.PA/
*SANOFI 3Q BUSINESS EPS EU3.55, EST. EU2.80
October 30, 2026 at 6:32 AM
*SANOFI 3Q BUSINESS EPS EU3.55, EST. EU2.80
Franse farmareus Sanofi trekt jaarprognose op
Het Franse farmabedrijf Sanofi, dat een grote voetafdruk heeft in ons land, verhoogt de omzet- en winstverwachting voor dit jaar.
Het Franse farmabedrijf Sanofi, dat een grote voetafdruk heeft in ons land, verhoogt de omzet- en winstverwachting voor dit jaar.
Franse farmareus Sanofi trekt jaarprognose op
Het Franse farmabedrijf Sanofi, dat een grote voetafdruk heeft in ons land, verhoogt de omzet- en winstverwachting voor dit jaar.
www.tijd.be
October 30, 2026 at 7:47 AM
Franse farmareus Sanofi trekt jaarprognose op
Het Franse farmabedrijf Sanofi, dat een grote voetafdruk heeft in ons land, verhoogt de omzet- en winstverwachting voor dit jaar.
Het Franse farmabedrijf Sanofi, dat een grote voetafdruk heeft in ons land, verhoogt de omzet- en winstverwachting voor dit jaar.
⬆️ #Covid19 #BioNTech #impfxfg #nuvaxfg #impflp81 #Comirnaty #Impfung #Impfstelle #Apotheke #Moosach #München #Bayern #TeamVernunft #ImpfenSchützt
Auch #XFG & #Sanofi #Novavax #Nuvaxovid (Selbstzahler), aber nur L.P.8.1 auf Kasse.
Mo-Fr 9-17 Uhr ohne Termin, sonst mit: moosach.marys-apotheke.de
Auch #XFG & #Sanofi #Novavax #Nuvaxovid (Selbstzahler), aber nur L.P.8.1 auf Kasse.
Mo-Fr 9-17 Uhr ohne Termin, sonst mit: moosach.marys-apotheke.de
October 30, 2026 at 8:16 AM
⬆️ #Covid19 #BioNTech #impfxfg #nuvaxfg #impflp81 #Comirnaty #Impfung #Impfstelle #Apotheke #Moosach #München #Bayern #TeamVernunft #ImpfenSchützt
Auch #XFG & #Sanofi #Novavax #Nuvaxovid (Selbstzahler), aber nur L.P.8.1 auf Kasse.
Mo-Fr 9-17 Uhr ohne Termin, sonst mit: moosach.marys-apotheke.de
Auch #XFG & #Sanofi #Novavax #Nuvaxovid (Selbstzahler), aber nur L.P.8.1 auf Kasse.
Mo-Fr 9-17 Uhr ohne Termin, sonst mit: moosach.marys-apotheke.de
⬆️ #Covid19 #BioNTech #impfxfg #nuvaxfg #impflp81 #Comirnaty #Impfung #Impfstelle #Apotheke #Papenburg #Emsland #Niedersachsen #TeamVernunft #ImpfenSchützt
Auch #XFG & #Sanofi #Novavax #Nuvaxovid (Selbstzahler), aber nur L.P.8.1 auf Kasse.
@drmccoy.info @safeairdocs.bsky.social @bildungabersicher.net
Auch #XFG & #Sanofi #Novavax #Nuvaxovid (Selbstzahler), aber nur L.P.8.1 auf Kasse.
@drmccoy.info @safeairdocs.bsky.social @bildungabersicher.net
October 28, 2026 at 8:33 AM
⬆️ #Covid19 #BioNTech #impfxfg #nuvaxfg #impflp81 #Comirnaty #Impfung #Impfstelle #Apotheke #Papenburg #Emsland #Niedersachsen #TeamVernunft #ImpfenSchützt
Auch #XFG & #Sanofi #Novavax #Nuvaxovid (Selbstzahler), aber nur L.P.8.1 auf Kasse.
@drmccoy.info @safeairdocs.bsky.social @bildungabersicher.net
Auch #XFG & #Sanofi #Novavax #Nuvaxovid (Selbstzahler), aber nur L.P.8.1 auf Kasse.
@drmccoy.info @safeairdocs.bsky.social @bildungabersicher.net
*SANOFI RAISES FY SALES, BUSINESS EPS GROWTH EX-FX GUIDANCE
October 30, 2026 at 6:30 AM
*SANOFI RAISES FY SALES, BUSINESS EPS GROWTH EX-FX GUIDANCE
Sanofi vola in Borsa a Parigi dopo conti oltre le attese
October 30, 2026 at 11:24 AM
Sanofi vola in Borsa a Parigi dopo conti oltre le attese
💉 #pharma
🇫🇷 Sanofi raised its 2026 outlook again: sales growth low teens, business EPS mid teens (July: sales about 10%).
Q3 at constant currency: sales €14.4bn, +14.3%; #Dupixent €5.7bn, +34.8%, 39% of sales; #Beyfortus −15.4% (US −39.3%).
midgardfinance.com/companies/SAN.PA/
🇫🇷 Sanofi raised its 2026 outlook again: sales growth low teens, business EPS mid teens (July: sales about 10%).
Q3 at constant currency: sales €14.4bn, +14.3%; #Dupixent €5.7bn, +34.8%, 39% of sales; #Beyfortus −15.4% (US −39.3%).
midgardfinance.com/companies/SAN.PA/
October 30, 2026 at 8:20 AM
💉 #pharma
🇫🇷 Sanofi raised its 2026 outlook again: sales growth low teens, business EPS mid teens (July: sales about 10%).
Q3 at constant currency: sales €14.4bn, +14.3%; #Dupixent €5.7bn, +34.8%, 39% of sales; #Beyfortus −15.4% (US −39.3%).
midgardfinance.com/companies/SAN.PA/
🇫🇷 Sanofi raised its 2026 outlook again: sales growth low teens, business EPS mid teens (July: sales about 10%).
Q3 at constant currency: sales €14.4bn, +14.3%; #Dupixent €5.7bn, +34.8%, 39% of sales; #Beyfortus −15.4% (US −39.3%).
midgardfinance.com/companies/SAN.PA/
Sanofi lifts expectations for 2026 sales growth, looks to M&A
Sanofi lifts expectations for 2026 sales growth, looks to M&A
By Bhanvi Satija LONDON, Oct 30 (Reuters) - French drugmaker Sanofi said on Friday it expects sales to grow by a "low-teens percentage" this year, up from a previous forecast
www.centraloregondaily.com
October 30, 2026 at 7:20 AM
Sanofi lifts expectations for 2026 sales growth, looks to M&A
$SNY Sanofi reported its results. Shares +6.1% today.
Why: "Sanofi Q3 earnings blow past expectations on Dupixent strength; hikes FY guidance" (Investing.com)
Analysts expected EPS of $1.63. Biggest one-day gain in a year.
Why: "Sanofi Q3 earnings blow past expectations on Dupixent strength; hikes FY guidance" (Investing.com)
Analysts expected EPS of $1.63. Biggest one-day gain in a year.
October 30, 2026 at 1:14 PM
$SNY Sanofi reported its results. Shares +6.1% today.
Why: "Sanofi Q3 earnings blow past expectations on Dupixent strength; hikes FY guidance" (Investing.com)
Analysts expected EPS of $1.63. Biggest one-day gain in a year.
Why: "Sanofi Q3 earnings blow past expectations on Dupixent strength; hikes FY guidance" (Investing.com)
Analysts expected EPS of $1.63. Biggest one-day gain in a year.
Under new CEO Garijo, #$SNY says it may pursue larger acquisitions while lifting 2026 growth targets after strong Dupixent-led Q3 results. notreload.xyz/xy/sanofi-op...
Sanofi Open to Bigger M&A as Dupixent Cliff Nears
Under new CEO Garijo, Sanofi says it may pursue larger acquisitions while lifting 2026 growth targets after strong Dupixent-led Q3 results.
notreload.xyz
October 30, 2026 at 11:41 AM
Under new CEO Garijo, #$SNY says it may pursue larger acquisitions while lifting 2026 growth targets after strong Dupixent-led Q3 results. notreload.xyz/xy/sanofi-op...
October 30, 2026 at 10:09 AM
Sanofi a ouvert en hausse de 4,1 % ce matin.
Trente minutes plus tard, à 9h25, l'action fait +6,1 %.
D'après Investing com France : Pourquoi l’action Sanofi s’envole-t-elle aujourd’hui ?.
Vous seriez monté dans le train ?
Trente minutes plus tard, à 9h25, l'action fait +6,1 %.
D'après Investing com France : Pourquoi l’action Sanofi s’envole-t-elle aujourd’hui ?.
Vous seriez monté dans le train ?
October 30, 2026 at 8:41 AM
Sanofi a ouvert en hausse de 4,1 % ce matin.
Trente minutes plus tard, à 9h25, l'action fait +6,1 %.
D'après Investing com France : Pourquoi l’action Sanofi s’envole-t-elle aujourd’hui ?.
Vous seriez monté dans le train ?
Trente minutes plus tard, à 9h25, l'action fait +6,1 %.
D'après Investing com France : Pourquoi l’action Sanofi s’envole-t-elle aujourd’hui ?.
Vous seriez monté dans le train ?
Sanofi : les ventes du médicament Dupixent s'envolent - 30/10
Ce vendredi 30 octobre, Maxime Le Juez, gérant GSD Gestion, s'est penché sur le carton du traitement Dupixent de Sanofi, la solide performance de Capgemini, la chute du Crédit Agricole en Bourse malgré un T3 solide, la hausse des...
Ce vendredi 30 octobre, Maxime Le Juez, gérant GSD Gestion, s'est penché sur le carton du traitement Dupixent de Sanofi, la solide performance de Capgemini, la chute du Crédit Agricole en Bourse malgré un T3 solide, la hausse des...
Sanofi : les ventes du médicament Dupixent s'envolent - 30/10
VIDÉO - Ce vendredi 30 octobre, Maxime Le Juez, gérant GSD Gestion, s'est penché sur le carton du traitement Dupixent de Sanofi, la solide performance de Capgemini, la chute du Crédit Agricole en Bour...
www.bfmtv.com
October 30, 2026 at 3:34 PM
Sanofi : les ventes du médicament Dupixent s'envolent - 30/10
Ce vendredi 30 octobre, Maxime Le Juez, gérant GSD Gestion, s'est penché sur le carton du traitement Dupixent de Sanofi, la solide performance de Capgemini, la chute du Crédit Agricole en Bourse malgré un T3 solide, la hausse des...
Ce vendredi 30 octobre, Maxime Le Juez, gérant GSD Gestion, s'est penché sur le carton du traitement Dupixent de Sanofi, la solide performance de Capgemini, la chute du Crédit Agricole en Bourse malgré un T3 solide, la hausse des...